CN1228332A - Drug for curing migraine and its preparing method - Google Patents
Drug for curing migraine and its preparing method Download PDFInfo
- Publication number
- CN1228332A CN1228332A CN98121890A CN98121890A CN1228332A CN 1228332 A CN1228332 A CN 1228332A CN 98121890 A CN98121890 A CN 98121890A CN 98121890 A CN98121890 A CN 98121890A CN 1228332 A CN1228332 A CN 1228332A
- Authority
- CN
- China
- Prior art keywords
- rhizoma chuanxiong
- rhizoma
- medicine
- volatile oil
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种治疗偏头痛(头风)的药物及其制作方法。它是以川芎、天麻为原料,根据每味中药的不同特性分别制取稠浸膏,并提取川芎挥发油,将稠浸膏制取干粉,在干粉中加入聚乙二醇400和川芎挥发油,混匀,采用压制法制成软胶囊。本发明配方及制作方法独特,治疗效果显著。The invention discloses a medicine for treating migraine (head wind) and a preparation method thereof. It uses Chuanxiong and Gastrodia elata as raw materials. According to the different characteristics of each traditional Chinese medicine, thick extracts are prepared respectively, and the volatile oil of Chuanxiong is extracted. The thick extract is made into dry powder, and polyethylene glycol 400 and Chuanxiong volatile oil are added to the dry powder. Uniformly, adopt compression method to make soft capsule. The formula and the preparation method of the invention are unique, and the therapeutic effect is remarkable.
Description
The present invention treats migraine remedy, is the Chinese patent medicine soft capsule of feedstock production with Chinese medicine specifically, the invention still further relates to the manufacture method of this medicine.
Migraine is a kind of common frequently-occurring disease, and (1992) such as U.S. Stewart adopt questionnaire method, obtain 20468 parts of test papers, and age distribution is 12-80 year, and the migraine sickness rate is as a result: the women 17.6%, and the male 6%.Henry etc. (1992) have investigated French migraine incidence rate with international standard, and the age, standard class was similar to the migraine research that the U.S. adopts more than 15 years old, and the migraine Epidemiological study result who draws is: the women 17.6%, and the male 6.1%.It is about 9% that various countries average attack rate male is grown up, and the women is grown up about 16%.It is 4.7: 3.51 that the women is higher than the male.There are non-linear relation at migraine prevalence and age.Both sexes increased with the age below 40 years old, then reduced later in 40 years old.
The record of domestic data, national each province and city in 1986, autonomous region (except that Taiwan Province) migraine Epidemiological study, total population is totally 383597 people, checks out patient's 37808 examples altogether, and its prevalence is 985.2/10 ten thousand populations, is higher than nineteen eighty-two and 1984 years survey result.Ascendant trend in migrainous prevalence, the sickness rate is described, but still is lower than external report.
Because migraine not only prevalence, sickness rate is higher, outbreak repeatedly, touching difficulty more and causes great misery to the patient, has a strong impact on its healthy and work.
The migrainous Chinese patent medicine of existing treatment such as a kind of name are called the hard capsule of " ZHENNAONING ", and its prescription contains Rhizoma Chuanxiong, Rhizoma Gastrodiae, Radix Salviae Miltiorrhizae, Medulla sus domestica, Herba Asari.Most flavour of a drug in the prescription are filled in the hard capsule for the simple medicated powder form of making of pulverizing, and bioavailability is low, and dose is big, and effective component content is relatively low.
The purpose of this invention is to provide a kind of bioavailability height, the active constituent content height, produce effects is fast, and side effect is little, the migrainous medicine of the treatment of taking convenience.
Another object of the present invention provides this preparation method for the treatment of migrainous medicine.
The present invention excavates from motherland's medicine treasure-house, utilizes modern means of science and technology, method and technology, the compound Chinese medicinal preparation of development high-efficiency high-quality.But this medicine blood circulation promoting and blood stasis dispelling is suffered from the wind pain relieving.Cure mainly stagnation of blood stasis, the headache battle array due to the wind-yang and up-boring is done, distending pain, jumping pain or twinge, i.e. migraine in the modern medicine.The present invention filters out Rhizoma Chuanxiong and Rhizoma Gastrodiae by the theory of Chinese medical science prescription.Rhizoma Chuanxiong is the gas medicine in the blood in the side, can blood circulation promoting and blood stasis dispelling, again can activating QI to alleviate the depression, and be to control headache and the main medicine of wind syndrome of head, having again nourishes blood transfers the effect of liver.Rhizoma Gastrodiae is longer than the suppressing the hyperactive liver and subsiding YANG endogenous wind stopping in the side, and is rather good to headache, dizzy curative effect due to the excessive rising of liver-YANG, and tranquil calm merit is arranged.Rhizoma Chuanxiong is that monarch drug, Rhizoma Gastrodiae are ministerial drug, two medicine compatibilities, and row looses and subduing the hyperactivity of YANG is harmonious, and at institute's smelting symptom and pathogenesis, the merit of giving consideration to both the incidental and fundamental is arranged, and adjuvant such as PEG400 are filler in the side, are convenient to make than capsule.
Of the present invention being achieved in that
Medicine of the present invention is the soft capsule made from the raw material of following weight ratio and method:
Rhizoma Chuanxiong 2-10 part
Rhizoma Gastrodiae 1-5 part
Rhizoma Chuanxiong with said ratio, Rhizoma Gastrodiae is produced thick extractum respectively, and extraction Rhizoma Chuanxiong volatile oil, extract dry powder is produced in thick extractum merging, in dry powder, add adjuvant and Rhizoma Chuanxiong volatile oil, mixing, wherein Rhizoma Chuanxiong, Rhizoma Gastrodiae extract powder and Rhizoma Chuanxiong volatile oil: 2-4 part, adjuvant: 6-8 part, adopt pressing to make soft capsule.
The best proportioning of the weight of each raw material of the present invention is:
4 parts of Rhizoma Chuanxiongs
1 part in Rhizoma Gastrodiae
In preparation, medicine and adjuvant weight proportion are:
Rhizoma Chuanxiong, Rhizoma Gastrodiae extract powder and Rhizoma Chuanxiong volatile oil: 3 parts
PEG400: 7 parts.
Manufacture method of the present invention is with the Rhizoma Chuanxiong distillation of proportioning, collects volatile oil and aqueous solution respectively, the Rhizoma Chuanxiong medicinal residues is decocted extract filtrate, and filtrate and aqueous solution are merged, the high heart of high speed, resin absorption, washing, reuse ethanol elution, collect eluent, recovery ethanol gets the thick extractum of Rhizoma Chuanxiong to there not being the alcohol flavor; With the Rhizoma Gastrodiae ethanol extraction, get extracting solution, reclaim ethanol and do not distinguish the flavor of thin up, cold preservation or high speed centrifugation to there being alcohol, be concentrated into the thick paste shape, add ethanol, leave standstill, filter, decompression recycling ethanol gets the thick extractum of Rhizoma Gastrodiae to nothing alcohol flavor, thick extractum of Rhizoma Gastrodiae and the thick extractum of Rhizoma Chuanxiong is merged the dry extract dry powder that gets; Get adjuvant, add extract dry powder and Rhizoma Chuanxiong volatile oil, mixing adopts pressing, makes soft capsule.
Adjuvant among the present invention can be PEG400, polyethylene glycol 6000, Oleum Arachidis hypogaeae semen, Oleum Glycines, Oleum Sesami, salad wet goods.
The present invention cures mainly according to we's function, and composition is accepted or rejected, and extracts active ingredient targetedly, removes impurity to greatest extent.What fill in the soft capsule is Chinese medicine extract, and dosing is few, taking convenience, and produce effects is fast, the bioavailability height.
The Pharmacodynamic test of active extract result of medicine of the present invention shows:
One, to the influence of experiment type migraine animal model c-fos expression of gene: medicine of the present invention can obviously suppress experiment type migraine animal model brain stem and hypothalamus cells c-fos expression of gene.
Two, calm experiment: each group of medicine of the present invention to after the administration 30,60,90 and during 120min the mice autonomic activities have remarkable inhibition to do.Medicine of the present invention is not seen the obvious synergistic effect to the pentobarbital sodium of sub-threshold dose.
Three, analgesic experiment: medicine 1.6g crude drug in whole/kg of the present invention and 5.8g crude drug in whole/kg group has inhibitory action to 0.7% glacial acetic acid induced mice writhing response, can make the writhing response prolongation of latency, turn round the body number of times in the 15min and reduce, 5.8g crude drug in whole/kg group mice hot plate pain stimulation has certain analgesic activity.
Four, to the microcirculatory influence of rat mesentery: medicine of the present invention is to by little restoration of blood flow time that is equipped with pipe of the rat mesentery due to the adrenalin hydrochloride solution, blood vessel (fine motion, dwindling vein), (the fine motion of blood fluidised form, slowing down or the minimizing of the open number of stagnation and point of intersect of the capillary network etc. vein), all improve significantly, illustrated that medicine of the present invention has that significant to improve the microcirculatory effect of mesentery (stronger with 60g crude drug in whole/kg dosage effect for the rat preduodenal administration, 12.0g crude drug in whole/kg dosage effect is taken second place, 3.0g crude drug in whole/kg dosage effect is not obvious).
Five, platelet is discharged the influence of 5-HT: medicine of the present invention has extremely significantly antiplatelet release 5-HT effect (P＜0.001) at 11.66～2.92g crude drug in whole/kg dosage range, and maximum release suppression ratio is 46.33%, and is tangible dose-effect relationship.
Six, to the effect of vascular endothelial cell calcium channel: 11.66 and 8.75g crude drug in whole/kg medicine of the present invention the effect (P＜0.001) of significantly resistance system vascular endothelial cell calcium channel is arranged extremely, suppression ratio is respectively 47.12% and 44.79%, and its effect is tangible dose-effect relationship in 11.66～2.92g crude drug in whole/kg dosage range.
Seven, to the influence of rabbit platelet aggregation: continuous 7 days gastric infusions, medicine of the present invention obviously reduces arachidonic acid and collagen-induced rabbit platelet aggregation rate (P＜0.005～0.01), and the inductive rabbit platelet aggregation rate of adenosine diphosphate (ADP) is had reduction trend.Point out medicine of the present invention to have the effect of anticoagulant.
Eight, external thrombus is formed and the influence of blood viscosity: continuous 7 days gastric infusions, medicine of the present invention significantly shorten thrombosis length (P＜0.05～0.001), alleviate wet weight of thrombus and dry weight (P＜0.01～0.001); Obviously reduce high, medium and low whole blood viscosity (P＜0.05～0.01) of cutting under the speed.Point out medicine of the present invention to have and suppress the effect that external thrombus forms, reduces whole blood viscosity.
Nine, to the hemorheological influence of anesthetized dog: medicine of the present invention is to having the reduction effect by whole blood reduced viscosity increase due to the Detran, be 5.8 to irritate stomach 60min and dosage to dog, 2.9g crude drug in whole/kg group is particularly remarkable, 1.16g crude drug in whole/kg group only has effect trend, after the administration 30, the 90min effect is all not obvious.Medicine of the present invention has the reduction effect to being increased by whole blood reduced viscosity due to the Detran, (be 5.8 to irritate stomach 60min and dosage to dog, 2.9g crude drug in whole/kg group is particularly remarkable, administration 90min takes second place, and behind 1.16g crude drug in whole/kg group and the administration 30min effect trend is only arranged.
Ten, to the influence of experimental dog cerebral ischemia: medicine 5.8 of the present invention, 2.9g crude drug in whole/kg can make the ischemic region scope of middle cerebral artery ligation significantly dwindle (P＜0.01～0.001), the ischemic region brain heavily accounts for full brain and heavily is respectively 14.42% and 18.01%, illustrates that medicine of the present invention has the effect that improves cerebral ischemia; ALP, CK activity significantly raise before than administration in the anesthetized dog ligation middle cerebral artery bleeding from anus, illustrate that the middle cerebral artery ligation causes ischemic tissue's damage, activity rising to ALP behind the medicine of the present invention and CK significantly reduces, and shows that medicine of the present invention has significant improvement effect to the tissue injury due to the experimental cerebral ischemia.
The safety test of medicine of the present invention shows:
(1) acute toxicity test
The present invention forms medicine and is nontoxic product, and this product fails to measure median lethal dose(LD 50), and maximum tolerated dose is for being grown up consumption more than 300 times, so drug safety.
(2) long term toxicity test
General inspection, hematological examination, blood biochemistry checking, the inspection of Liver and kidney merit all belong to range of normal value.Histopathologic examination's no abnormality seen, and spleen B cellular regions and T cellular regions have in various degree and enlarge, and prompting this product may have the effect that promotes liquid immunity and cellular immunization.
The migrainous clinical preliminary observation of Drug therapy of the present invention is as follows:
(1) object and method
1, object:
Press IHS1998 migraine diagnostic criteria Huaxi Medical Univ's emergency treatment and outpatient service prescription on individual diagnosis patient in May, 1998 to June 10.Include standard in and exclusion standard is the same.The patient is totally 31 examples.
2, method:
By at random, double blinding, placebo-controlled trial.
Be divided into two groups: 16 examples are organized in (1) treatment, 2 Tid * 3 of medicine of the present invention time.
(2) matched group 15 examples, 2 Tid * 3 of placebo time.
(2) curative effect discrimination standard:
Produce effects: heavy or moderate headache → slight → disappearance
Effectively: heavy, in, slight headache → in, light and disappear
Severe: lie up
Moderate: can not adhere to work
Slightly: can adhere to work
(3) observation index:
1. have a headache 2. simultaneous phenomenon 3. hemorheology learn 4. transcranial doppler (5. three big routines, EEO rabat, Liver and kidney merit, electrolyte, blood fat, blood glucose
(4) observed result
Medicine of the present invention is to treating migrainous side effect:
Medicine of the present invention (n=16) placebo (n=15)
Three big conventional (-) (-)
EEG (-) (-)
Rabat (-) (-)
Liver, kidney merit (-) (-)
Electrolyte (-) (-)
Feel sick 11
Stomach upset 51
Dizzy 20
Medicine of the present invention is to the influence of blood rheology parameter
Medicine of the present invention (n=16) placebo (n=15)
Rear HCT (%) 38.25 ± 5.32 38.20 ± 6.12 38.45 ± 5.71 38.36 ± 5.80 η plasma 1.21 for the treatment of ± 0.52 11.3 ± 0.64 1.18 ± 0.48 1.75 ± 0.53 (mpas) η, 0.512 23.51 ± 5.28 21.42 ± 5.11* 25.37 ± 5.14 24.11 ± 4.97 (mpas) η 5.12 5.17 ± 1.86 5.31 ± 1.73 5.21 ± 2.01 5.13 ± 2.77 (mpas) * shows that P＜0.05 Low Shear30 (Switzerland) medicine of the present invention is on the impact of migraineur's cerebral artery blood flow velocity before treating after treating before the treatment
Medicine of the present invention (n=16) placebo (n=15)
The interior tremulous pulse 45.64 ± 4.g 43.6 of treatment collare ± 5.7 42.6 ± 5.1 43.44 ± 4.4 middle cerebral arterys 58.2 ± 8.3 50.5 ± 5.9* 57.6 ± 9.3 55.1 ± 8.8 vertebral artery 34.1 ± 5.2 35.2 ± 6.4 35.71 ± 6.4 35.9 ± 7.5* represent P＜0.05 T＜2000 (Germany) before treating the back treatment before the treatment
Medicine of the present invention is to the influence of migraineur's platelet 5-HT
Medicine of the present invention (n=16) placebo (n=15)
Ng/ 3582 ± 627 4437 ± 583* 3979 ± 787 3814 ± 838*P＜0.01 clinical observation in treatment back before the treatment of treatment back before the treatment
Medicine of the present invention (n=16) placebo (n=15) age (year) 374 ± 11 38 ± 12
Man 54
Woman's 11 11 age of onset (year) 204 ± 10 20 ± 10 migraine types have tendency 32 absence of aura 13 13 every month attack times 4 ± 34 ± 3 not treat duration of seizure (h) 53 ± 28 54 ± 30 attack degree when flat
Light by 24
In 10 8
Weigh the clinical practice of 4 relevant outbreak 56 medicines of the present invention with menstruation
It is effective in adult's migraine phase that medicine of the present invention (n=16) placebo (n=15) outbreak worsens 00 (five) brief summaries medicinal application of the present invention apart from administration time 0-4hr 10 8＞hr 67 produce effects 50 effective 74 invalid 4 11: medicine of the present invention can be used for common and classic antimigraine, is the wide spectrum migraine remedy. Medicine of the present invention has multiple pharmacology mechanism migraine.
The adult is good to Drug tolerance of the present invention.
Embodiment:
Take by weighing raw material by following proportioning:
1 kilogram in 4 kilograms of Rhizoma Gastrodiaes of Rhizoma Chuanxiong
0.5 kilogram of PEG400
Production method is as follows:
After getting the Rhizoma Chuanxiong thin slice and soaking the heart, heating distillation extraction 6 hours is collected volatile oil; Aqueous solution after distillation device is in addition collected; The Rhizoma Chuanxiong medicinal residues decoct with water and extract 1 time, filter, and the aqueous solution after filtrate and the distillation merges high speed centrifugation, cross macroporous adsorptive resins, first water flushing discards water lotion, reuse 70% concentration ethanol eluting, the collection eluent, decompression recycling ethanol gets the thick extractum of Rhizoma Chuanxiong to there not being the alcohol flavor; Get the Rhizoma Gastrodiae coarse granule, with 70% alcohol reflux 3 times, merge alcohol extract, decompression recycling ethanol is to there not being the alcohol flavor, thin up is to certain volume, cold preservation or high speed centrifugation, the medicinal liquid reconcentration after the processing be to the thick paste shape, adds ethanol and make and contain the alcohol amount and reach 90%, leave standstill, filtration, decompression recycling ethanol gets the thick extractum of Rhizoma Gastrodiae to there not being the alcohol flavor; Thick extractum of above-mentioned Rhizoma Chuanxiong and the thick extractum of Rhizoma Gastrodiae are merged, and spray drying or vacuum drying get Rhizoma Chuanxiong and Rhizoma Gastrodiae extract dry powder; Taking polyethylene glycol 400 adds Rhizoma Chuanxiong and Rhizoma Gastrodiae extract dry powder, and the limit edged is stirred to even, adds Rhizoma Chuanxiong volatile oil again, and mixing adopts pressing, makes soft capsule.
Claims (3)
1, the medicine of a kind of treatment migraine (wind syndrome of head) is characterized in that it is the soft capsule made from the raw material and the method for following weight ratio:
Rhizoma Chuanxiong 2-10 part
Rhizoma Gastrodiae 1-5 part
Rhizoma Chuanxiong with said ratio, Rhizoma Gastrodiae is produced thick extractum respectively, and extraction Rhizoma Chuanxiong volatile oil, extract dry powder is produced in thick extractum merging, in dry powder, add adjuvant and Rhizoma Chuanxiong volatile oil, mixing, wherein Rhizoma Chuanxiong, Rhizoma Gastrodiae extract powder and Rhizoma Chuanxiong volatile oil: 2-4 part, adjuvant 6-8 part adopts pressing to make soft capsule.
2, medicine according to claim 1 is characterized in that the optimum weight proportioning of each raw material is:
4 parts of Rhizoma Chuanxiongs
1 part in Rhizoma Gastrodiae
In preparation, medicine and adjuvant weight proportion are:
Rhizoma Chuanxiong, Rhizoma Gastrodiae extract powder and Rhizoma Chuanxiong volatile oil: 1 part
PEG400: 4 parts.
3, the manufacture method of the medicine of a kind of treatment migraine according to claim 1 (wind syndrome of head), it is characterized in that Rhizoma Chuanxiong distillation with described proportioning, collect volatile oil and aqueous solution respectively, the Rhizoma Chuanxiong medicinal residues are decocted extract filtrate, filtrate and aqueous solution are merged, the high heart of high speed, washing, the reuse ethanol elution is collected eluent, recovery ethanol gets the thick extractum of Rhizoma Chuanxiong to there not being the alcohol flavor; With the Rhizoma Gastrodiae ethanol extraction, get extracting solution, reclaim ethanol and do not distinguish the flavor of thin up, cold preservation or high speed centrifugation to there being alcohol, be concentrated into the thick paste shape, add ethanol, leave standstill, filter, recovery ethanol gets the thick extractum of Rhizoma Gastrodiae to nothing alcohol flavor, thick extractum of Rhizoma Gastrodiae and the thick extractum of Rhizoma Chuanxiong is merged the dry extract dry powder that gets; Get adjuvant, add extract dry powder and Rhizoma Chuanxiong volatile oil, mixing adopts pressing, makes soft capsule.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98121890A CN1067901C (en) | 1998-12-03 | 1998-12-03 | Drug for curing migraine and its preparing method |
| DE19958427A DE19958427A1 (en) | 1998-12-03 | 1999-12-03 | Drug for curing migraine and the preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98121890A CN1067901C (en) | 1998-12-03 | 1998-12-03 | Drug for curing migraine and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1228332A true CN1228332A (en) | 1999-09-15 |
| CN1067901C CN1067901C (en) | 2001-07-04 |
Family
ID=5227387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98121890A Expired - Lifetime CN1067901C (en) | 1998-12-03 | 1998-12-03 | Drug for curing migraine and its preparing method |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN1067901C (en) |
| DE (1) | DE19958427A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100417386C (en) * | 2005-10-17 | 2008-09-10 | 秦引林 | Compound medicament composed of gastrodine and ligustrazine |
| CN100417406C (en) * | 2003-06-24 | 2008-09-10 | 江苏康缘药业股份有限公司 | A drop pill preparation for treating angioneurotic headache |
| CN102091240A (en) * | 2011-01-24 | 2011-06-15 | 南京中医药大学 | Szechuan lovage rhizome formula micro emulsion nasal delivery preparation and preparation method and application thereof |
| CN105194350A (en) * | 2015-10-29 | 2015-12-30 | 赵卫国 | Traditional Chinese medicine composition for treating migraine, preparation method and medicines for traditional Chinese medicine composition |
| CN110655483A (en) * | 2018-06-28 | 2020-01-07 | 成都中医药大学 | A kind of alkaloid compound and its preparation method and use |
| CN110963956A (en) * | 2019-12-13 | 2020-04-07 | 成都中医药大学 | Preparation method of new phenylalamine alkaloid |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115624603B (en) * | 2022-09-07 | 2023-09-01 | 南阳理工学院 | Traditional Chinese medicine composition for treating migraine and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1101557A (en) * | 1993-10-09 | 1995-04-19 | 周耀群 | Naomaitong oral liquid and its preparation method |
-
1998
- 1998-12-03 CN CN98121890A patent/CN1067901C/en not_active Expired - Lifetime
-
1999
- 1999-12-03 DE DE19958427A patent/DE19958427A1/en not_active Withdrawn
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100417406C (en) * | 2003-06-24 | 2008-09-10 | 江苏康缘药业股份有限公司 | A drop pill preparation for treating angioneurotic headache |
| CN100417386C (en) * | 2005-10-17 | 2008-09-10 | 秦引林 | Compound medicament composed of gastrodine and ligustrazine |
| CN102091240A (en) * | 2011-01-24 | 2011-06-15 | 南京中医药大学 | Szechuan lovage rhizome formula micro emulsion nasal delivery preparation and preparation method and application thereof |
| CN102091240B (en) * | 2011-01-24 | 2012-07-04 | 南京中医药大学 | Szechuan lovage rhizome formula micro emulsion nasal delivery preparation and preparation method and application thereof |
| CN105194350A (en) * | 2015-10-29 | 2015-12-30 | 赵卫国 | Traditional Chinese medicine composition for treating migraine, preparation method and medicines for traditional Chinese medicine composition |
| CN110655483A (en) * | 2018-06-28 | 2020-01-07 | 成都中医药大学 | A kind of alkaloid compound and its preparation method and use |
| CN110655483B (en) * | 2018-06-28 | 2023-03-31 | 成都中医药大学 | Alkaloid compound and preparation method and application thereof |
| CN110963956A (en) * | 2019-12-13 | 2020-04-07 | 成都中医药大学 | Preparation method of new phenylalamine alkaloid |
| CN110963956B (en) * | 2019-12-13 | 2023-05-16 | 成都中医药大学 | Preparation method of amphetamine type novel alkaloid |
Also Published As
| Publication number | Publication date |
|---|---|
| DE19958427A1 (en) | 2000-06-21 |
| CN1067901C (en) | 2001-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103006769B (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN104815166B (en) | A kind of Chinese medicine composition for treating diabetes and its preparation and application | |
| CN1228332A (en) | Drug for curing migraine and its preparing method | |
| CN1824177A (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN101716269B (en) | Traditional Chinese medicine composition for treating hyperpiesia | |
| CN105267559B (en) | A kind of drug and preparation method thereof for treating diabete peripheral herve pathology | |
| CN103830584B (en) | Medicine for the treatment of Vertebral Artery Ischemic Disease and preparation method thereof | |
| CN101732585A (en) | Medicinal composition for treating migraine, preparation method and application thereof | |
| CN106581109A (en) | Cerebral thrombosis treating pharmaceutical composition | |
| CN1296087C (en) | Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof | |
| CN1931294A (en) | Chinese medicine composition for treating ischemic apoplexy and its prepn process | |
| CN100512840C (en) | Chinese medicine for treating hypertension, diabetes and coronary heart disease caused by atherosclerosis | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN106860495A (en) | Fat-reducing liver-protecting Chinese medicine composition | |
| CN100396279C (en) | A kind of traditional Chinese medicine preparation for treating arrhythmia and preparation method thereof | |
| CN1927279A (en) | Chinese medicine composition for treating skin disease | |
| CN104352819A (en) | Traditional Chinese medicine composition for treating transient tic disorder and preparation method of traditional Chinese medicine composition | |
| CN1927324A (en) | Preparation method of traditional medicine preparation for treating women's menoxenia | |
| CN1883533A (en) | Pharmaceutical composition for treating apoplexy and preparation method thereof | |
| CN112206279B (en) | Traditional Chinese medicine composition for treating ventricular arrhythmia and preparation method and application thereof | |
| CN103263581A (en) | Shuangshen capsule for reducing blood sugar | |
| CN1248722C (en) | Medicine for treating coronary heart disease and preparation method thereof | |
| CN1935171A (en) | Medicinal composition and its preparing method | |
| CN1857607A (en) | Chinese medicine preparation for treating cardiac and cerebral vascular diseases and its preparing process | |
| CN1679746A (en) | a medicine for constipation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Co-applicant after: Taiji Pharmaceutical Co., Ltd., Sichuan Prov. |
|
| CB03 | Change of inventor or designer information |
Inventor after: Wang Yitao Inventor after: Bai Lixi Inventor after: Wu Chunjie Inventor after: Li Sicheng Inventor after: Yang Ming Inventor after: Qing Yuling Inventor before: Wu Chunjie Inventor before: Wang Yitao Inventor before: Yang Ming Inventor before: Li Sicheng Inventor before: Wang Xing |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WU CHUNJIE; WANG YITAO; YANG MING; LI SICHENG; WANG XING TO: WANG YITAO; BAI LIXI; WU CHUNJIE; LI SICHENG; YANG MING; QING YULING |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20010704 |
|
| CX01 | Expiry of patent term |